Relevant bibliographies by topics / Antimitotic

Academic literature on the topic 'Antimitotic'

Author: Grafiati
Published: 4 June 2021
Last updated: 9 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antimitotic.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antimitotic"

1

Campos, Susana M., and Don S. Dizon. "Antimitotic Inhibitors." Hematology/Oncology Clinics of North America 26, no. 3 (June 2012): 607–28. http://dx.doi.org/10.1016/j.hoc.2012.01.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Groult, Hugo, Isabel García-Álvarez, Lorenzo Romero-Ramírez, Manuel Nieto-Sampedro, Fernando Herranz, Alfonso Fernández-Mayoralas, and Jesús Ruiz-Cabello. "Micellar Iron Oxide Nanoparticles Coated with Anti-Tumor Glycosides." Nanomaterials 8, no. 8 (July 25, 2018): 567. http://dx.doi.org/10.3390/nano8080567.

Full text
Abstract:
The synthesis procedure of nanoparticles based on thermal degradation produces organic solvent dispersible iron oxide nanoparticles (OA-IONP) with oleic acid coating and unique physicochemical properties of the core. Some glycosides with hydrophilic sugar moieties bound to oleyl hydrophobic chains have antimitotic activity on cancer cells but reduced in vivo applications because of the intrinsic low solubility in physiological media, and are prone to enzymatic hydrolysis. In this manuscript, we have synthetized and characterized OA-IONP-based micelles encapsulated within amphiphilic bioactive glycosides. The glycoside-coated IONP micelles were tested as Magnetic Resonance Imaging (MRI) contrast agents as well as antimitotics on rat glioma (C6) and human lung carcinoma (A549) cell lines. Micelle antimitotic activity was compared with the activity of the corresponding free glycosides. In general, all OA-IONP-based micellar formulations of these glycosides maintained their anti-tumor effects, and, in one case, showed an unusual therapeutic improvement. Finally, the micelles presented optimal relaxometric properties for their use as T2-weighed MRI contrast agents. Our results suggest that these bioactive hydrophilic nano-formulations are theranostic agents with synergistic properties obtained from two entities, which separately are not ready for in vivo applications, and strengthen the possibility of using biomolecules as both a coating for OA-IONP micellar stabilization and as drugs for therapy.
APA, Harvard, Vancouver, ISO, and other styles
3

Hamel, Ernest, and David Covell. "Antimitotic Peptides and Depsipeptides." Current Medicinal Chemistry-Anti-Cancer Agents 2, no. 1 (November 14, 2012): 19–53. http://dx.doi.org/10.2174/1568011023354263.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Santhakumari, G., and J. Stephen. "Antimitotic effects of holothurin." CYTOLOGIA 53, no. 1 (1988): 163–68. http://dx.doi.org/10.1508/cytologia.53.163.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

R. A. Ahirrao, B. S. Patange, and S. V. More. "Evaluation of Antimitotic Activity of Momordica Dioica Fruits on Allium Cepa Root Meristamatic Cells." Journal of Pharmaceutical Technology, Research and Management 7, no. 2 (November 5, 2019): 67–71. http://dx.doi.org/10.15415/jptrm.2019.72009.

Full text
Abstract:
Objective: Natural occurring phenolic compounds play an important role in cancer prevention and shows antimitotic activity. Number of active constituents like phenolic acid, curcuminoids, coumarine, ligans, quinones, etc. is showing antimitotic activity of Momordica dioica. The present work is on phytochemical investigation and examines antimitotic activity of aqueous extract of fruits Momordica dioica at concentration of 15 mg/ml on Allium cepa root meristamatic cells.Methods: The fruits are air dried and extracted with solvents like water by maceration method. The evaluation of antimitotic activity is done by using Allium cepa root meristamatic cells parameters where and methotrexate was used as a standard drugs. Result and discussion: In Allium assay, aqueous extract of fruits of Momordica diocia (15 mg/ml) and methotrexate act against cells of allium roots and lesser the growth of root and mitotic index when compared with distilled water as control group. The result indicated that cytotoxic property is due to presence of phenolic, alkaloids and flavonoids compounds in 15 mg/ml concentration of aqueous extract of Momordica diocia fruits extract.Conclusion: On the basis of result, we concluded that, 15 mg/ml concentration of Momordica dioica fruits shows good antimitotic activity on the Allium cepa root tip assay.
APA, Harvard, Vancouver, ISO, and other styles
6

Sundaresan, K., M. Thangavel, and K. Tharini. "Synthesis, characterization and antimitotic activity of N-benzyl piperidin 4-one oxime." Journal of Drug Delivery and Therapeutics 9, no. 1 (January 15, 2019): 233–36. http://dx.doi.org/10.22270/jddt.v9i1.2228.

Full text
Abstract:
The aim of this study was to synthesize, characterization and antimitotic activity of N-Benzyl piperidin 4-one oxime derivative. The synthesized compound was characterized by IR, 13C and 1H NMR spectral studies. The synthesized compound was subjected to antimitotic studies of alliumcepa root meristamatic cells. The mitotic activity was observed in 3 different concentrations of N-Benzyl piperidin 4-one oxime. Our findings support the reported therapeutic use of this compound as a antimitotic or anticancer agent in the Indian system of medicine. Keywords: N-Benzyl piperidin 4-one oxime, meristamatic cells, mitotic index.
APA, Harvard, Vancouver, ISO, and other styles
7

Nagle, Advait, Wooyoung Hur, and Nathanael Gray. "Antimitotic Agents of Natural Origin." Current Drug Targets 7, no. 3 (March 1, 2006): 305–26. http://dx.doi.org/10.2174/138945006776054933.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tarkowska, Jadwiga A. "Sodium cacodylate as antimitotic agent." Acta Societatis Botanicorum Poloniae 57, no. 3 (2014): 329–40. http://dx.doi.org/10.5586/asbp.1988.032.

Full text
Abstract:
The effect of pure sodium cacodylate on dividing cells was studied. The root meristematic cells of <em>Allium cepa</em> L. (the roots were squashed in acetoorcein) and endosperm cells of <em>Haemanthus katherinae</em> Bak. (<em>in vitro</em> observations) were used. Serious disturbances in karyokinesis and cytokinesis were found that led most often to the formation of polyploid or multinucleate (<em>A. cepa</em>) cells. These results point to damage of the mitotic spindle and phragmoplast. Careful use of cacodylate buffer in ultrastructural studies of microtubules is advised.
APA, Harvard, Vancouver, ISO, and other styles
9

Dall'Acqua, Stefano. "Natural Products As Antimitotic Agents." Current Topics in Medicinal Chemistry 14, no. 20 (December 12, 2014): 2272–85. http://dx.doi.org/10.2174/1568026614666141130095311.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Perez-Melero, Concepcion. "KSP Inhibitors as Antimitotic Agents." Current Topics in Medicinal Chemistry 14, no. 20 (December 12, 2014): 2286–311. http://dx.doi.org/10.2174/1568026614666141130095532.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antimitotic"

1

Yuen, Tsz Ying. "Enantioselective total synthesis of the antimitotic agent paecilospirone." Thesis, University of Auckland, 2011. http://hdl.handle.net/2292/10767.

Full text
Abstract:
This thesis describes the first, enantioselective total synthesis of the marine natural product paecilospirone (1). Paecilospirone is a polyketide derived metabolite isolated from the marine fungus Paecilomyces sp. collected off the coast of Yap Island, Federated States of Micronesia. Structural assignment following anticancer bioassay subsequently revealed a novel spiro[chroman-2,1(3H)- isobenzofuran] core where an -hydroxyl group occupies the unusual axial position of the sixmembered tetrahydropyran ring. An efficient and flexible strategy was developed to provide access to the [5,6]-bisbenzannulated spiroacetal in a convergent manner. Three key fragments, bromide 162, aldehyde 120 and ketone 92, were synthesised using readily available starting materials. In particular, ketone 92 was obtained from the chiral pool, thus allowing the facile incorporation of enantioselectivity into the synthesis. The fragments were successfully coupled together using an aryllithiation addition and a diasteresoselective, anti-boron aldol reaction. Initial attempts at the late stage spiroacetalisation reaction focused on the acid-mediated cyclisation of MOM-protected ketone 112. However, upon spirocyclisation, 113 readily underwent elimination to afford the corresponding dehydrated products. The problem was exacerbated by the axial orientation of the oxygenated group positioned to the spirocentre and anti to a vicinal hydrogen atom, thus a revision in protecting group strategy was enforced whereby access to the spiroacetal core was envisioned using pH neutral conditions. Attention therefore focused on the model study of a dihydroxyketone equivalent (123) in which the alcohol groups were protected as allyl ethers. Accordingly, treatment of 123 with Pd(PPh3)4 in the presence of a range of silane addictives successfully furnished the desired spiroacetal 124, clearly demonstrating the synthetic utility of this method for the preparation of sensitive spiroacetal systems. Subjection of bis-allyl ketone 166 to the established reaction conditions ultimately led to the completion of the total synthesis of paecilospirone 1.
Whole document restricted until Jan. 2014, but available by request, use the feedback form to request access.
APA, Harvard, Vancouver, ISO, and other styles
2

Findlay, A. D. "Total synthesis and structural assignment of antimitotic polyketides." Thesis, University of Cambridge, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.599022.

Full text
Abstract:
The first part of this dissertation describes the revised stereochemical assignment of the cytotoxic marine macrolide dolastain 19, isolated from the sea hare Dolabella auricularia, which was proposed and subsequently validated by completion of the first total synthesis. Based upon molecular modelling and common biogenetic considerations, four of the twelve stereocentres of the originally proposed structure 50 were inverted in configuration. The carbon backbone 56 of this stereochemically reassigned 14-membered macrolide 54 was assembled using an asymmetric vinylogous Mukaiyama aldol reaction, in combination with boron aldol methodology. A Mukaiyama glycosylation was employed to append the required L-rhamose-derived sugar unit 44. Overall the synthesis was completed in 23 steps and 1.7% overall yield. The second part of this dissertation focuses on the myxobacterium-derived natural product, spirangien A (124). Initial work centred on the preparation of an advanced diene degradation fragment 134, and the subsequent assignment of absolute configuration. The use of a common stereotetrad intermediate 149 was crucial in the development of a convergent and step-economic synthetic strategy. Two series of reactions were performed to access 234 and 148, before recombination via aldol coupling. Elaboration of linear spiroacetalisation precursor 244 provided synthetic spirangien diene 134. Measurement of the optical rotation and comparison with available literature data for natural 134 then enabled the confident assignment of the complete stereochemistry of spirangien A. Laterally, studies focussed on the extension of this synthetic strategy to enable the completion of the total synthesis of spirangien A.
APA, Harvard, Vancouver, ISO, and other styles
3

Healy, M. "Studies towards the C1-C17 fragment of the potent antimitotic spongistatin 1." Thesis, University of Cambridge, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.603922.

Full text
Abstract:
This thesis is divided into 7 chapters. Chapter 1 describes the history of the spongistatin family. The isolation of the spongistatins, cinachyrolide and the altohyrtins is reviewed. The structural assignments of these molecules is then discussed and their common identities highlighted. A discussion of the biological properties of the spongistatins then follows before summarising the structural features of the molecules and the issues they pose towards a total synthesis. The spiroketal fragments of the spongistatins are then examined more closely. Spiroketal containing natural products and synthetic methods towards spiroketals are then reviewed. Chapter 2 reviews the synthetic work which has been conducted towards the total synthesis of the spongistatins, paying attention to the 4 groups who have so far completed a total synthesis of one of the spongistatin molecules. Chapter 3 is a review of the strategy our group has taken towards the total synthesis of spongistatin 1. The synthesis of major fragments is described and synthetic problems that have been encountered and have led to a change in the strategy towards the AB spiroketal containing, C1-C17 fragment of spongistatin 1. Chapter 4 outlines the new strategy towards the C1-C17 fragment of spongistatin 1. Synthesis of the C8-C17 fragment is described in detail, with particular attention paid to functionalisation of the C13 alkene via a Wacker oxidation, Shapiro reaction and higher-order cuprate addition to a C12 epoxide. Coupling of a C8 aldehyde with an anomeric phosphonium salt is discussed, and the need for another change is strategy is outlined. Chapters 5 describes the new route to the AB spiroketal via a 1,3-diketone. Synthesis of this fragment is described, and modifications made due to protecting group issues are described in detail, culminating in the successful synthesis of the AB spiroketal. An exciting unified approach to the AB and CD spiroketals is then summarised in Chapter 6.
APA, Harvard, Vancouver, ISO, and other styles
4

Hodgkinson, Julie L. "The effect of ligands on the assembly of tubulin polymers." Thesis, Liverpool John Moores University, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.292340.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Genovino, Julien. "Studies towards the total synthesis of (+)-spirastrellolide A." Thesis, University of Cambridge, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.608940.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Shojania, Feizabadi Mitra. "Physical Concepts of Copolymerization of Microtubules in the Presence of Anti-mitotic Agents." Diss., Virginia Tech, 2005. http://hdl.handle.net/10919/27795.

Full text
Abstract:
A mathematical approach to the concepts of copolymerization of microtubules in the presence of anti-mitotic drugs is presented in this work. A general feature of the mathematical equations is presented. The possibility of having analytical steady state solutions of dynamic equations is investigated. The structure of equations is narrowed down for the specific brand of anti-mitotic drug, colchicine. The behavior of total T-tubulin concentration in the steady state in a regeneration system is investigated and analyzed through the numerical calculations.
Ph. D.
APA, Harvard, Vancouver, ISO, and other styles
7

Wolmarans, Elize. "In vitro induction of the apoptotic intrinsic pathway via a new antimitotic agent." Diss., University of Pretoria, 2014. http://hdl.handle.net/2263/79212.

Full text
Abstract:
Unique, in silico-designed compounds with possible anticancer properties were identified in our laboratory. 2-Ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16), with potential carbonic anhydrase IX inhibiting activity, is capable of interfering with microtubule dynamics. In this study, it was investigated whether ESE-16 is capable of inducing apoptosis in vitro in the esophageal carcinoma SNO cell line via the intrinsic pathway at a concentration of 0.2μM with an exposure time of 24 hours. Qualitative results were obtained via polarization-optical transmitted light differential interference contrast microscopy, light microscopy, transmission electron microscopy and confocal microscopy. Results showed hallmarks of apoptosis in the ESE-16-treated cells. In addition, data revealed an increase in the number of ESE-16-treated cells blocked in metaphase. Cell death via apoptosis in the ESE-16-treated cells was confirmed by studying the internal ultrastructure of the cells via transmission electron microscopy, while confocal microscopy revealed abnormal spindle formation and condensed chromatin in ESE-16-treated cells, confirming metaphase block. Quantitative results were obtained via flow cytometry and spectrophotometry. Cell death via apoptosis in ESE-16-treated cells were quantitatively confirmed by cell cycle progression analysis and the Annexin V-FITC apoptosis detection assay. Metaphase block due to ESE-16 exposure was confirmed by demonstrating an increase in cyclin B levels in the ESE-16-treated cells. In addition, flow cytometry and spectrophotometry revealed dissipation of mitochondrial membrane potential, an increase in superoxide levels, changes in the redox status and an increase in cytochrome c levels in the cytosol of the ESE-16-treated cells. Both initiator caspase 9 and effector caspase 3 activities were increased, which demonstrates that ESE-16 causes cell death in a caspase-dependent manner. This was the first in vitro study conducted to investigate the action mechanism of ESE-16 on an esophageal carcinoma cell line. The results provided valuable information on the action mechanism of this potential anticancer agent. It can be concluded that the novel in silico-designed compound exerts an anti-proliferative effect on the esophageal carcinoma SNO cell line by disrupting microtubule function resulting in metaphase block. This culminates in apoptotic cell death via the intrinsic apoptotic pathway. This research provided cellular targets warranting in vivo assessment of ESE-16’s potential as an anticancer agent.
Dissertation (MSc)--University of Pretoria, 2014.
Physiology
MSc
Unrestricted
APA, Harvard, Vancouver, ISO, and other styles
8

Golebiowska, Katarzyna. "Identification and development of new antimitotic molecules based on the synergistic effect of fragments." Université Louis Pasteur (Strasbourg) (1971-2008), 2005. http://www.theses.fr/2005STR13167.

Full text
Abstract:
In vivo, les microtubules – les fibres constitutives du cytosquelette – résultent de l’assemblage longitudinal de 13 protofilaments parallèles par addition (ou polymérisation) des hétérodimères constitués de deux sous unités  et  de la tubuline. Ces sont des polymères dont l’équilibre dynamique avec les monomèrs, est crucial lors de la mitose et la division cellulaire. La perturbation ou le blocage de cette dynamique conduit généralement à la mort cellulaire. Dans le cadre de cette thèse, nous nous sommes intéressés à la découverte de nouveaux composés simples qui conduisent, comme les produits naturels complexes (le Taxol®, les épothilones, l’éleutherobine et le discodermolide) à la stabilisation des microtubules par inhibition de leur dépolymérisation. Pour réaliser notre objectif, nous avons dans un premier temps synthétisé une collection d’acides carboxyliques, fragments dérivés de l’épothilone, l’éleutherobine et d’autres hétérocycles non naturels, ainsi que différentes amines secondaires dans le but de constituer plusieurs librairies d’amides. Pour l’identification rapide des chimiothèques les plus actives nous avons développé et mis au point une stratégie de criblage et plusieurs déconvolutions ont permis d’identifier les structures des composés des mélanges responsables de la stabilisation des microtubules. L’observation d’un effet synergique entre deux molécules nous a permis ensuite d’optimiser la structure des molécules et de développer de nouveaux ligands plus actifs. Parallèlement à ces travaux nous avons également étudié la localisation du site de liaison des taxoides, et donc de nos molécules. Des études préliminaires réalisées avec du TaxAPU, un photoanalogue de Taxol® radiomarqué, et avec des microtubules sous forme cylindriques et sous forme de feuillets de zinc ont montré que les sous unités  de la tubuline sont marquées de façon similaire, dans un rapport de 30/70
The key fibre components of the cytoskeleton, microtubules, are formed in vivo by the longitudinal assembly of 13 protofilaments via the addition (polymerisation) of heterodimers of α- and β- subunits of tubulin. They are hollow, tubular fibres whereby dynamic equilibrium is crucial for mitosis and cell division. The perturbation or arrest of their assembly/disassembly leads to cell apoptosis. During the course of this thesis, we were interested in the discovery of new, simple compounds via a fragment-based approach, that are similar to more complex, natural products such as Taxol®. These compounds stabilise the microtubules by inhibition of their disassembly. To realise our aim, we have initially synthesised a collection of different carboxylic acids and secondary amines, the fragments derived form epothilone, eleutherobin and other natural heterocycles that were used to build the libraries of amides. In order to evaluate the biological activity of the amide libraries, we have adopted the microtubule disassembly-based screening that allowed rapid identification of the most active library. Several deconvolutions led us to consequently identify the chemical structures of components being responsible for the stabilisation of microtubules. The observation of the synergistic effect between two active molecules led us to improve their chemical structures and to obtain the ligands with enhanced biological activity. In parallel to this work, we have focused on the first photoaffinity labeling studies of zinc-induced tubulin sheets that could potentially allow for the localisation of the taxoids binding site on microtubules. The preliminary results of the photoaffinity labeling of zinc-induced tubulin sheets and microtubules in the cylindrical form with [3H] TaxAPU, the Taxotere® photoanalogue, have showed that the α- and β-subunits of tubulin are labeled in both these forms in approximately the same ratio 30/70
APA, Harvard, Vancouver, ISO, and other styles
9

Zang, Qin. "Towards the total synthesis of peloruside A analogues." Laramie, Wyo. : University of Wyoming, 2008. http://proquest.umi.com/pqdweb?did=1663059931&sid=1&Fmt=2&clientId=18949&RQT=309&VName=PQD.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Xu, Lin. "Novel G2 cell cycle checkpoint inhibitors and antimitotic agents isolated through two new HTS bioassays." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2001. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/NQ61207.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Antimitotic"

1

Goudot-Perrot, Andrée. Metabolic inhibitors: Antibiotics - antimitotics - psychotropics. Stuttgart: Schwer Verlag, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Baktir, Afaf. Isolasi dan uji antimitosis komponen dalam Scurrula atropurpurea (BL) danser. Surabaya: Lembaga Penelitian, Universitas Airlangga, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Antimitotic"

1

Bousbaa, Hassan. "Antimitotic Drugs." In Encyclopedia of Cancer, 1–2. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_7074-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bousbaa, Hassan. "Antimitotic Drugs." In Encyclopedia of Cancer, 286–88. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-46875-3_7074.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hernigou, P., P. Brun, J. P. Thierry, M. C. Voisin, G. Delepine, and D. Gout Allier. "Antimitotic-Loaded Acrylic Cement." In Limb Salvage, 163–67. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-75879-9_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dousset, N., A. M. Loudet, A. Lespine, M. Carton, L. Douste-Blazy, and H. Chap. "Apolipoproteins Induced by an Antimitotic Agent." In Advances in Experimental Medicine and Biology, 201–8. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-1268-0_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sinzinger, H., P. Fitscha, and H. Kritz. "Antimitotic actions of vasodilatory prostaglandins — clinical aspects." In Prostaglandins and Control of Vascular Smooth Muscle Cell Proliferation, 92–106. Basel: Birkhäuser Basel, 1997. http://dx.doi.org/10.1007/978-3-0348-7352-9_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ecsedy, Jeffrey A., Mark Manfredi, Arijit Chakravarty, and Natalie D’Amore. "Current and Next Generation Antimitotic Therapies in Cancer." In Signaling Pathways in Cancer Pathogenesis and Therapy, 5–21. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4614-1216-8_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rodier, Patricia M. "Behavioral Effects of Antimitotic Agents Administered during Neurogenesis." In Handbook of Behavioral Teratology, 185–209. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4613-2189-7_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Palumbo, G. "A Photochemical Approach to Study the Antimitotic-Drugs Tubulin Interaction." In Topics in Molecular Organization and Engineering, 369–79. Dordrecht: Springer Netherlands, 1994. http://dx.doi.org/10.1007/978-94-011-0822-5_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Commerçon, A., J. D. Bourzat, E. Didier, and François Lavelle. "Practical Semisynthesis and Antimitotic Activity of Docetaxel and Side-Chain Analogues." In ACS Symposium Series, 233–46. Washington, DC: American Chemical Society, 1994. http://dx.doi.org/10.1021/bk-1995-0583.ch017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shih, Chuan, Rima S. Al-Awar, Andrew H. Fray, Michael J. Martinelli, Eric D. Moher, Bryan H. Norman, Vinod F. Patel, et al. "Synthesis and Structure-Activity Relationship Studies of Cryptophycins: A Novel Class of Potent Antimitotic Antitumor Depsipeptides." In Anticancer Agents, 171–89. Washington, DC: American Chemical Society, 2001. http://dx.doi.org/10.1021/bk-2001-0796.ch010.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antimitotic"

1

Florian, Stefan, Deepak R. Chittajallu, Rainer H. Kohler, James D. Orth, Peter K. Sorger, Ralph Weissleder, Gaudenz Danuser, and Timothy J. Mitchison. "Abstract A297: Microtubule targeting antimitotic drugs induce a lower mitotic arrest than clinically less effective antimitotic Eg5 inhibitors in mouse xenografts." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-a297.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Aldonza, Mark Borris D. "Abstract 2118: Collateral resistance trajectories following failure to antimitotic drugs." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2118.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Aldonza, Mark Borris D. "Abstract 2118: Collateral resistance trajectories following failure to antimitotic drugs." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2118.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Senter, Peter. "Abstract SY28-02: Tumor targeting with antimitotic monoclonal antibody drug conjugates." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-sy28-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wilson, Catherine, Thinh Pham, Xiaofen Ye, Eva Lin, Sara Chan, Erin McNamara, Richard M. Neve, et al. "Abstract 693: AXL tyrosine kinase inhibition selectively sensitizes mesenchymal cancer cells to antimitotic agents." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-693.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Punganuru, Surendra Reddy, Sadanandam Palle, Kaushlendra Tripathi, and Komaraiah Palle. "Abstract 2475: Design and development of combretastatin based unsymmetrical terphenyls as small molecule antimitotic agents." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2475.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jiang, Xiaoyu, Hua Li, Ping Zhao, Jingping Xie, Dineo Khabele, Junzhong Xu, and John C. Gore. "Abstract 4214: Assessment of early antimitotic treatment response in ovarian cancer using temporal diffusion spectroscopy." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4214.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Burke, Patrick J., Joseph Z. Hamilton, Thomas A. Pires, Kim K. Emmerton, Peter D. Senter, and Scott C. Jeffrey. "Abstract A097: Tubulysin ADC payloads: An antimitotic drug class that retains activity in multidrug resistant models." In Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1535-7163.targ-19-a097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Spanò, Virginia, Daniele Giallombardo, Alessandra Montalbano, Anna Carbone, Eugenio Gaudio, Roberta Bortolozzi, Ruoli Bai, et al. "Abstract C097: Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles: A new class of antimitotic agents." In Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1535-7163.targ-19-c097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lobert, Sharon, and Mary E. Graichen. "Abstract 4347: Interphase reduction in ZEB1 and tubulin isotypes in breast cancer cells associated with antimitotic drug treatment." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-4347.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antimitotic"

1

Roberge, Michel. Identification and Characterization of Novel Antimitotic Compounds for the Treatment of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2001. http://dx.doi.org/10.21236/ada396662.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Roberge, Michel. Identification and Characterization of Novel Antimitotic Compounds for the Treatment of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2000. http://dx.doi.org/10.21236/ada383238.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Roberge, Michel. Identification and Characterization of Novel Antimitotic Compounds for the Treatment of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2002. http://dx.doi.org/10.21236/ada409399.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mitchell, Miguel O. Prostate Specific Antigen-Triggered Prodrug of S-Trityl-L-Cysteine, an Eg5 Kinesin Inhibitor and Antimitosis Agent with Low Neurotoxicity. Fort Belvoir, VA: Defense Technical Information Center, August 2008. http://dx.doi.org/10.21236/ada488600.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mitchell, Miguel O. Prostate Specific Antigen-Triggered Tripartate Prodrug of S-trityl-L-Cysteine, an Eg5 Kinesin Inhibitor and Antimitosis Agent with Low Neurotoxicity. Fort Belvoir, VA: Defense Technical Information Center, February 2008. http://dx.doi.org/10.21236/ada800539.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antimitotic' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography